NYSE:AORTMedical Equipment
Will FDA Approval Of NEXUS And Endospan Option Reshape Artivion's (AORT) Minimally Invasive Aortic Strategy
Artivion, Inc. recently announced that the FDA has approved the PMA for Endospan’s NEXUS Aortic Arch System, triggering a 90‑day window in which Artivion can exercise its option to acquire Endospan, supported by a US$150 million delayed draw term loan arranged in advance.
NEXUS, backed by TRIOMPHE trial data showing strong one‑year outcomes in high‑risk aortic arch patients, could broaden Artivion’s presence in minimally invasive aortic repair where alternatives to open‑chest surgery have...